HER2 gene amplification assessed by in situ hybridization (ISH) or protein overexpression assessed by IHC remains the primary predictor of responsiveness to HER2- targeted therapies and a key prognostic biomarker in breast cancer [6]. This evidence concerns the gene ERBB2 and breast carcinoma.